The novel angiotensin II receptor blocker azilsartan medoxomil ameliorates insulin resistance induced by chronic angiotensin II treatment in rat skeletal muscle

CardioRenal Medicine

Volumn 3, Issue 2, 2013, Pages 154-164

  Lastra, Guido ^a   Santos, Fernando R ^b   Hooshmand, Payam ^b   Hooshmand, Paria ^b   Mugerfeld, Irina ^a   Aroor, Annayya R ^a   Demarco, Vincent G ^a   Sowers, James R ^a   Henriksen, Erik J ^b  

^a University of Missouri   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Akt; AMPK; Angiotensin II; AS160; Glucose transport; p70 S6K1; Red skeletal muscle

Indexed keywords

ANGIOTENSIN II DERIVATIVE; AZILSARTAN MEDOXOMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; GASTROCNEMIUS MUSCLE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SOLEUS MUSCLE;

EID: 84896690840     PISSN: 16643828     EISSN: 16645502     Source Type: Journal    
DOI: 10.1159/000353155     Document Type: Article

References (40)

1. Watson KE, Peters Harmel AL, Matson G: Atherosclerosis in type 2 diabetes mellitus: the role of insulin resistance. J Cardiovasc Pharmacol Therapeut 2003; 8: 253-260.
2. Kim JA, Montagnani M, Koh KK, Quon MJ: Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113: 1888-1904.
3. Cooper SA, Whaley-Connell A, Habibi J, Wei Y, Lastra G, Manrique C, et al: Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007; 293:H2009-H2023.
4. Henriksen EJ: Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am J Physiol Regulatory Integrative Comp Physiol 2007; 293:R974-R980.
5. Zhou MS, Schulman IH, Zeng Q: Link between the renin-angiotensin system and insulin resistance: implications for cardiovascular disease. Vasc Med 2012; 17: 330-341.
6. DeFronzo RA, Ferrannini E, Hendler R, Felig P, Wahren J: Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man. Diabetes 1983; 32: 32-45.
7. Baron AD, Brechtel G, Wallace P, Edelman SV: Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans. Am J Physiol Endocrinol Metab 1988; 255:E769-E774.
8. Richey JM, Ader M, Moore D, Bergman RN: Angiotensin II induces insulin resistance independent of changes in interstitial insulin. Am J Physiol Endocrinol Metab 1999; 277:E920-E926.
9. Ogihara T, Asano T, Ando K, Chiba Y, Sakoda H, Anai M, Shojima N, Ono H, Onishi Y, Fujishiro M, et al: Angio-tensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002; 40: 872-879.
10. Diamond-Stanic MK, Henriksen EJ: Direct inhibition by angiotensin II of insulin-dependent glucose transport activity in mammalian skeletal muscle involves a ROS-dependent mechanism. Arch Physiol Biochem 2010; 116:88-95.
11. Lastra G, Habibi J, Whaley-Connell AT, Manrique C, Hayden MR, Rehmer J, et al: Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology 2009; 150: 2561-2568.
12. Marchionne EM, Diamond-Stanic MK, Prasonnarong M, Henriksen EJ: Chronic renin inhibition with aliskiren improves glucose tolerance, insulin sensitivity, and skeletal muscle glucose transport activity in obese Zucker rats. Am J Physiol Regul Integ Comp Physiol 2012; 302:R137-R142.
13. Henriksen EJ, Jacob S: Angiotensin converting enzyme inhibitors and modulation of insulin resistance. Diabetes Obes Metab 2003; 5: 214-222.
14. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M: Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001; 38: 884-890.
15. Blendea MC, Jacobs D, Stump CS, McFarlane SI, Ogrin C, Bahtyiar G, et al: Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endo-crinol Metab 2005; 288:E353-E359.
16. Sloniger JA, Saengsirisuwan V, Diehl CJ, Kim JS, Henriksen EJ: Selective angiotensin II receptor antagonism enhances whole-body insulin sensitivity and muscle glucose transport in hypertensive TG(mREN2)27 rats. Metabolism 2005; 54: 1659-1668.
17. Lastra G, Whaley-Connell A, Manrique C, Habibi J, Gutweiler AA, Appesh L, et al: Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab 2008; 295:E110-E116.
18. Bosch J, Yusuf S, Gerstein H, Pogue J, Sheridan P, Dagenais G, et al: Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-1562.
19. Sharma AM, Engeli S: The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome. J Cardiometabolic Syndr 2006; 1: 29-35.
20. Baker WL, White WB: Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension. Ann Pharmacother 2011; 45: 1506-1515.
21. White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, et al: Effects of the angiotensin receptor blocker azil-sartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57: 413-420.
22. Kusumoto K, Igata H, Ojima M, Tsuboi A, Imanishi M, Yamaguchi F, et al: Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Eur J Pharmacol 2011; 669: 84-93.
23. Zhao M, Li Y, Wang J, Ebihara K, Rong X, Hosoda K, et al: Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. Diabetes Obes Metab 2011; 13: 1123-1129.
24. Zhou X, Ma L, Habibi J, Whaley-Connell A, Hayden MR, Tilmon RD, et al: Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension 2010; 55: 880-888.
25. DeMarco VG, Ford DA, Henriksen EJ, Aroor AR, Johnson MS, Habibi J, et al: Obesity-related alterations in cardiac lipid profile and nondipping blood pressure pattern during transition to diastolic dysfunction in male db/db mice. Endocrinology 2013; 154: 159-171.
26. Henriksen EJ, Jacob S: Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism 1995; 44: 267-272.
27. Hansen PA, Gulve EA, Holloszy JO: Suitability of 2-deoxyglucose for in vitro measurement of glucose transport activity in skeletal muscle. J Appl Physiol 1994;76: 979-985.
28. Henriksen EJ, Diamond-Stanic MK, Marchionne EM: Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radic Biol Med 2011; 51: 993-999.
29. Fujii N, Jessen N, Goodyear LJ: AMP-activated protein kinase and the regulation of glucose transport. Am J Physiol Endocrinol Metab 2006; 291:E867-E877.
30. Winder WW, Thomson DM: Cellular energy sensing and signaling by AMP-activated protein kinase. Cell Biochem Biophys 2007; 47: 332-347.
31. Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, Castel J, et al: mTOR inhibition by rapamycin prevents β-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008; 57: 945-957.
32. Khamzina L, Veilleux A, Bergeron S, Marette A: Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology 2005; 146: 1473-1481.
33. Tremblay F, Brule S, Hee Um S, Li Y, Masuda K, Roden M, et al: Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. PNAS 2007; 104: 14056-14061.
34. Zhang J, Gao Z, Yin J, Quon MJ, Ye J: S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-a signaling through IKK2. J Biol Chem 2008; 283: 35375-35382.
35. Kim JA, Jang HJ, Martinez-Lemus LA, Sowers JR: Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation. Am J Physiol Endocrinol Metab 2012; 302:E201-E208.
36. Lastra-Gonzalez G, Manrique C, Govindarajan G, Whaley-Connell A, Sowers J: Insights into the emerging cardiometabolic prevention and management of diabetes mellitus. Expert Opin Pharmacother 2005; 6: 2209-2221.
37. Solski LV, Longyhore DS: Prevention of type 2 diabetes mellitus with angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm 2008; 65: 935-940.
38. NAVIGATOR Study Group; McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, et al: Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1477-1490.
39. Kurtz TW: Beyond the class angiotensin-receptor-blocker profile. Nat Clin Pract Cardiovasc Med 2008; 5(suppl 1):S19-S26.
40. Kajiya T, Ho C, Wang J, Vilardi R, Kurtz TW: Molecular and cellular effects of azilsartan: a new generation angio-tensin II receptor blocker. J Hypertens 2011; 29: 2476-2483.